Tim Mayleben had a front-row seat as a board member to the shaky period two years ago when stem cell company Aastrom Biosciences was clinging to survival. Now, he’s in the driver’s seat as things are looking up for the publicly traded biotech firm. In 2012, Aastrom (Nasdaq: ASTM) could launch its first product–a treatment […]
Eight Ohio hospitals–from large teaching hospitals to medium-sized community hospitals–made Thomson Reuters’ 100 Top Hospitals: National Benchmarks list this year. To arrive at its annual report, Thomson Reuters evaluates hospital performance in 10 areas: mortality, medical complications, patient safety, average length of stay, expenses, profitability, patient satisfaction, adherence to clinical standards of care, and post-discharge […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Aastrom Biosciences Inc. has finished treating patients in a Phase 2 clinical trial of its cardiac-repair stem cells. The milestone clears the way for Aastrom to report six-month interim results of the trial later this year, according to a statement from the company. In the trial, Aastrom treated 40 patients suffering from dilated cardiomyopathy, a […]
Aastrom Biosciences, once in danger of being deslisted from the Nasdaq, has regained compliance with the stock exchange’s $1 minimum share price requirement. In December, the stem cell company was granted an extension until March 31 from being delisted. The company said its stock would have to trade above $1 for 10 consecutive days before […]
The last couple years have been a bumpy ride for Adeona Pharmaceuticals. The company nearly collapsed in the wake of an FDA rejection of its top drug candidate, Coprexa, in January 2008, and Adeona has had four different chief executives in the last 12 months. Perhaps seeking a divorce from the bad memories, the company […]
Stem cell company Aastrom Biosciences plans to begin a Phase 3 clinical trial of its treatment for critical limb ischemia. Critical limb ischemia results from a decreased blood supply, is often the endpoint of peripheral arterial disease and can lead to amputation. Aastrom said it will proceed with the Phase 3 trial of its vascular […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Adeona Pharmaceuticals has enrolled half of the patients it hopes to sign up for trials of its multiple sclerosis drug Trimesta. The company is in the midst of what it calls Phase "2/3" trials of Trimesta and has enrolled 75 of a planned 150 patients.
Aastrom Biosciences Inc. has completed a 1-for-8 reverse stock split that has so far achieved its desired effect--pushing the company's share price above $1 so it can remain listed on the Nasdaq stock exchange.
Esperion Therapeutics Inc., a spin-off from Pfizer Inc., has raised an additional $5 million to develop drugs that treat cardiovascular and metabolic disease, according to a SEC filing. The regulatory document states that Esperion has raised $27.75 million in equity and debt, but that dollar figure likely includes a $22.75 million Series A fundraise the company announced in 2008 after the spin-off.
Stem cell company Aastrom Biosciences announced an 8-for-1 reverse stock split in an attempt to avoid being delisted by the Nasdaq stock exchange.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
For the second time in less than a year, Adeona Pharmaceuticals has hired a new chief executive. Dr. James Kuo, who's served on the company's board since 2007, takes over as the company's CEO, president and chairman of the board.
The award marks the sixth patent the Ann Arbor-based company has received for its nanoemulsion technology, in which ultra-small particles of one liquid are suspended in a second liquid that won't mix with the first.
Aastrom, which is developing therapies that use stem cells to treat cardiovascular diseases, priced its shares at 26 cents per unit and hopes to raise $10.9 million from the offering.
Early stage health investor Arboretum Ventures has added George Dunbar, former chief executive of Michigan biotech company Aastrom Biosciences Inc., as a partner.
The University of Michigan spin-off, which also hired a new chief executive, plans to maintain its research and development operations in the Ann Arbor area.